What does CUSIP 04965N104 represent in this 13F holders report?

CUSIP 04965N104 is the security identifier for RNA - Atrium Therapeutics, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held RNA - Atrium Therapeutics, Inc. - COMMON STOCK in Q1 2026?

160 institutional investors reported RNA - Atrium Therapeutics, Inc. - COMMON STOCK for Q1 2026. Use the holders table for investor-level position and value details.

Atrium Therapeutics, Inc. - COMMON STOCK (RNA)

CUSIP: 04965N104

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class: Equity / COMMON STOCK
Total 13F shares: 14,832,543
Total 13F value: $198,321,325
Share change: +13,174,314
Put/Call ratio: 1729%
SEC-reported price per share: $13.37
Number of holders: 160
Value change: +$176,150,803
Number of buys: 154
Shares outstanding: 17,127,721

Security key

04965N104

Report period

Q1 2026

Institutions

160

Top holders

RNA full security history Ownership snapshot Full 13F holder table Atrium Therapeutics, Inc. SEC filings Atrium Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of RNA - Atrium Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Sarah Boyce

Disclosed value leader

—

Comparable rows

0/5

Latest evidence

27 Feb 2026

3/4/5 Some rows are evidence-backed but not safely comparable across classes. 5 rows are not safely comparable across share classes.

Quick read

SEC ownership evidence is available, but the rows are not safely comparable across share classes.

0 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Sarah Boyce's linked filing trail.

Detailed SEC evidence table Showing 1-5 of 5 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Sarah Boyce	3/4/5 Director 3/4/5	— mixed-class rows	— 285,086 shares mixed-class rows	—	27 Feb 2026
W. Michael Flanagan	3/4/5 Director 3/4/5	— mixed-class rows	— 74,786 shares mixed-class rows	—	27 Feb 2026
Troy E. Wilson	3/4/5 Director 3/4/5	— mixed-class rows	— 31,731 shares mixed-class rows	—	27 Feb 2026
Carsten Boess	3/4/5 Director 3/4/5	— mixed-class rows	— 31,005 shares mixed-class rows	—	27 Feb 2026
Simona Skerjanec	3/4/5 Director 3/4/5	— mixed-class rows	— 25,902 shares mixed-class rows	—	27 Feb 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

160

14,832,543

Rows available

160

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders

160

Q1 2026 holders

160

Holder diff

Investor	Q1 2026 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q1 2026 value	Q1 2026 value	Value change	Value Chg %